Header Logo

Connection

THOMAS MONATH to Viral Vaccines

Back to Details
This is a "connection" page, showing publications THOMAS MONATH has written about Viral Vaccines.
THOMAS MONATH
Connection Strength
7.217
Viral Vaccines
  1. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog. 2022 06; 18(6):e1010658.
    View in: PubMed
    Score: 0.637
  2. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015 Jan 01; 33(1):62-72.
    View in: PubMed
    Score: 0.375
  3. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006 Oct; 75(4):659-63.
    View in: PubMed
    Score: 0.214
  4. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006 Apr 25; 103(17):6694-9.
    View in: PubMed
    Score: 0.207
  5. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
    View in: PubMed
    Score: 0.206
  6. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005 Oct; 18(5):387-94.
    View in: PubMed
    Score: 0.200
  7. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals. 2005 Sep; 33(3):131-44.
    View in: PubMed
    Score: 0.199
  8. Recombination and flavivirus vaccines: a commentary. Vaccine. 2005 Apr 27; 23(23):2956-8.
    View in: PubMed
    Score: 0.194
  9. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol. 2004 Nov; 78(22):12497-507.
    View in: PubMed
    Score: 0.187
  10. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004 Nov; 71(5):639-45.
    View in: PubMed
    Score: 0.187
  11. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
    View in: PubMed
    Score: 0.181
  12. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
    View in: PubMed
    Score: 0.174
  13. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol. 2003 May; 33(5-6):567-82.
    View in: PubMed
    Score: 0.169
  14. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003; 61:469-509.
    View in: PubMed
    Score: 0.165
  15. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg Microbes Infect. 2022 Dec; 11(1):2724-2734.
    View in: PubMed
    Score: 0.164
  16. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis. 2002 Dec; 8(12):1392-7.
    View in: PubMed
    Score: 0.164
  17. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. J Infect Dis. 2022 10 17; 226(8):1401-1406.
    View in: PubMed
    Score: 0.163
  18. Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
    View in: PubMed
    Score: 0.162
  19. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002 Jun 20; 298(1):146-59.
    View in: PubMed
    Score: 0.159
  20. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
    View in: PubMed
    Score: 0.158
  21. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.155
  22. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol. 2002; 267:105-38.
    View in: PubMed
    Score: 0.154
  23. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
    View in: PubMed
    Score: 0.153
  24. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001 Aug; 75(16):7290-304.
    View in: PubMed
    Score: 0.150
  25. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med. 2001 Aug; 7(8):350-4.
    View in: PubMed
    Score: 0.150
  26. West Nile virus vaccine. Curr Drug Targets Infect Disord. 2001 May; 1(1):37-50.
    View in: PubMed
    Score: 0.147
  27. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine. 2020 11 17; 38(49):7708-7715.
    View in: PubMed
    Score: 0.141
  28. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. Vaccine. 2020 07 22; 38(34):5556-5561.
    View in: PubMed
    Score: 0.138
  29. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000 Jun; 74(12):5477-85.
    View in: PubMed
    Score: 0.138
  30. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
    View in: PubMed
    Score: 0.135
  31. Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases. Vaccine. 2019 10 08; 37(43):6248-6254.
    View in: PubMed
    Score: 0.131
  32. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
    View in: PubMed
    Score: 0.128
  33. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
    View in: PubMed
    Score: 0.127
  34. Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerg Infect Dis. 1998 Oct-Dec; 4(4):698-702.
    View in: PubMed
    Score: 0.123
  35. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 1997 Oct; 15(14):1494-502.
    View in: PubMed
    Score: 0.115
  36. Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine. 2016 12 12; 34(51):6610-6616.
    View in: PubMed
    Score: 0.105
  37. Stability of yellow fever vaccine. Dev Biol Stand. 1996; 87:219-25.
    View in: PubMed
    Score: 0.102
  38. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
    View in: PubMed
    Score: 0.083
  39. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990 May; 161(5):878-82.
    View in: PubMed
    Score: 0.069
  40. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.046
  41. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004 Jan; 78(2):1032-8.
    View in: PubMed
    Score: 0.044
  42. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg. 2004 Jan; 70(1):89-97.
    View in: PubMed
    Score: 0.044
  43. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol. 2003 Sep; 17(3):235-43.
    View in: PubMed
    Score: 0.043
  44. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus). Am J Trop Med Hyg. 2003 Jul; 69(1):78-80.
    View in: PubMed
    Score: 0.043
  45. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. J Gen Virol. 1983 Mar; 64 Pt 3:627-37.
    View in: PubMed
    Score: 0.042
  46. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology. 1983 Feb; 125(1):8-17.
    View in: PubMed
    Score: 0.042
  47. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg. 2002 Sep; 67(3):260-5.
    View in: PubMed
    Score: 0.040
  48. Facing up to re-emergence of urban yellow fever. Lancet. 1999 May 08; 353(9164):1541.
    View in: PubMed
    Score: 0.032
  49. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993 May-Jun; 87(3):337-9.
    View in: PubMed
    Score: 0.021
  50. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg. 1991 Jul; 45(1):1-43.
    View in: PubMed
    Score: 0.019
  51. Japanese encephalitis--a plague of the Orient. N Engl J Med. 1988 Sep 08; 319(10):641-3.
    View in: PubMed
    Score: 0.015
  52. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol. 1988 Aug; 69 ( Pt 8):1921-9.
    View in: PubMed
    Score: 0.015
  53. Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
    View in: PubMed
    Score: 0.012
  54. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg. 2005 Jan; 72(1):74-81.
    View in: PubMed
    Score: 0.012
  55. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984; 62(4):585-90.
    View in: PubMed
    Score: 0.011
  56. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59(6):895-900.
    View in: PubMed
    Score: 0.009
  57. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2000 Apr; 62(4):480-4.
    View in: PubMed
    Score: 0.009
  58. Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
    View in: PubMed
    Score: 0.006
  59. [Yellow fever in Senegal from 1976 to 1980 (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):45-51.
    View in: PubMed
    Score: 0.002
  60. Studies of glucose metabolism in rhesus monkeys after Venezuelan equine encephalitis virus infection. J Med Virol. 1980; 6(3):227-34.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.